Novogene Co., Ltd.

XSSC:688315 Stock Report

Market Cap: CN¥5.2b

Novogene Valuation

Is 688315 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688315 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688315 (CN¥12.88) is trading above our estimate of fair value (CN¥5.67)

Significantly Below Fair Value: 688315 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688315?

Key metric: As 688315 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688315. This is calculated by dividing 688315's market cap by their current earnings.
What is 688315's PE Ratio?
PE Ratio27.9x
EarningsCN¥187.24m
Market CapCN¥5.22b

Price to Earnings Ratio vs Peers

How does 688315's PE Ratio compare to its peers?

The above table shows the PE ratio for 688315 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.8x
301333 R&G PharmaStudies
46.2x27.0%CN¥5.6b
688222 HitGen
93.7x20.3%CN¥4.9b
688046 GemPharmatech
38.1x27.9%CN¥5.3b
688710 Shanghai Innostar Biotechnology
37.2xn/aCN¥5.5b
688315 Novogene
27.9x19.4%CN¥5.2b

Price-To-Earnings vs Peers: 688315 is good value based on its Price-To-Earnings Ratio (27.9x) compared to the peer average (53.8x).

Price to Earnings Ratio vs Industry

How does 688315's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
688315 27.9xIndustry Avg. 32.7xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688315 is good value based on its Price-To-Earnings Ratio (27.9x) compared to the Asian Life Sciences industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 688315's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688315 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.9x
Fair PE Ratio24.3x

Price-To-Earnings vs Fair Ratio: 688315 is expensive based on its Price-To-Earnings Ratio (27.9x) compared to the estimated Fair Price-To-Earnings Ratio (24.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688315 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥12.88
CN¥15.33
+19.0%
8.6%CN¥16.50CN¥13.48n/a3
Nov ’25CN¥12.67
CN¥15.33
+21.0%
8.6%CN¥16.50CN¥13.48n/a3
Oct ’25CN¥13.14
CN¥13.39
+1.9%
2.2%CN¥13.70CN¥13.00n/a3
Sep ’25CN¥10.36
CN¥13.39
+29.3%
2.2%CN¥13.70CN¥13.00n/a3
Aug ’25CN¥10.54
CN¥17.85
+69.4%
6.4%CN¥19.00CN¥16.70n/a2
Jul ’25CN¥11.01
CN¥17.85
+62.1%
6.4%CN¥19.00CN¥16.70n/a2
Jun ’25CN¥13.30
CN¥17.85
+34.2%
6.4%CN¥19.00CN¥16.70n/a2
May ’25CN¥14.30
CN¥21.48
+50.2%
24.3%CN¥28.75CN¥16.70n/a3
Apr ’25CN¥14.57
CN¥30.25
+107.6%
6.4%CN¥33.00CN¥28.75n/a3
Mar ’25CN¥15.70
CN¥30.25
+92.7%
6.4%CN¥33.00CN¥28.75n/a3
Feb ’25CN¥15.74
CN¥30.25
+92.2%
6.4%CN¥33.00CN¥28.75n/a3
Jan ’25CN¥23.34
CN¥30.25
+29.6%
6.4%CN¥33.00CN¥28.75n/a3
Dec ’24CN¥24.84
CN¥30.25
+21.8%
6.4%CN¥33.00CN¥28.75n/a3
Nov ’24CN¥22.25
CN¥34.41
+54.6%
15.4%CN¥41.47CN¥28.75CN¥12.673
Oct ’24CN¥22.60
CN¥37.60
+66.4%
9.3%CN¥41.47CN¥33.00CN¥13.143
Sep ’24CN¥22.13
CN¥37.60
+69.9%
9.3%CN¥41.47CN¥33.00CN¥10.363
Aug ’24CN¥27.12
CN¥40.70
+50.1%
4.2%CN¥42.30CN¥38.33CN¥10.543
Jul ’24CN¥26.55
CN¥42.55
+60.3%
2.3%CN¥43.88CN¥41.47CN¥11.013
Jun ’24CN¥31.68
CN¥42.55
+34.3%
2.3%CN¥43.88CN¥41.47CN¥13.303
May ’24CN¥35.49
CN¥42.55
+19.9%
2.3%CN¥43.88CN¥41.47CN¥14.303

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

7D

3.7%

1Y

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

7D

-1.8%

1Y

13.3%